Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maulik Bhalani

Interventional Pain Medicine Wesley Chapel, FL Medical Doctor

NPI 1336331008 CMS profile 196231

27810 Summergate Blvd, Wesley Chapel, FL 33544

Open in the dashboard

General payments

$20,401

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maulik Bhalani of Wesley Chapel, FL is reported in the CMS Open Payments database as having received $20,401 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,053 44
2024 General $7,702 45
2023 General $1,901 39
2022 General $3,932 61
2021 General $2,193 39
2020 General $934 23
2019 General $1,687 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maulik Bhalani
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Maulik Bhalani were reported at $2,053. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Maulik Bhalani Interventional Pain Medicine median Middle half National median
2019 $1,687 $684 $216–$2,079 $163
2020 $934 $382 $122–$1,109 $114
2021 $2,193 $552 $167–$1,554 $132
2022 $3,932 $605 $187–$1,924 $149
2023 $1,901 $671 $195–$1,915 $160
2024 $7,702 $684 $206–$1,837 $164
2025 $2,053 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $10,069 72 payments
  2. Abbott Laboratories $3,436 54 payments
  3. Boston Scientific Corporation $2,495 51 payments
  4. Stimwave Technologies Incorporated $562 9 payments
  5. Medtronic USA, Inc. $547 12 payments
  6. Relievant Medsystems, Inc. $472 8 payments
  7. Nevro Corp. $440 16 payments
  8. Foundation Fusion Solutions, LLC $281 4 payments
  9. Teva Pharmaceuticals USA, Inc. $269 5 payments
  10. Amgen Inc. $219 6 payments
  11. Other $1,611 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,562 274 payments
  2. Travel and Lodging $4,371 17 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,400 1 payment
  4. Education $46 2 payments
  5. Entertainment $23 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $8,282 56 payments
  2. PROCLAIM Neuromodulation $1,749 9 payments
  3. INTELLIS Spinal Cord Neurostimulation $1,055 4 payments
  4. WaveWriter Alpha Prime 16 $870 17 payments
  5. PROCLAIM Neuromodulation $539 11 payments
  6. Proclaim Family of SCS IPGs $507 10 payments
  7. General - Pain Management $427 5 payments
  8. INTELLIS Spinal Cord Neurostimulation $400 8 payments
  9. Intracept Pain $381 8 payments
  10. Intracept Pain $364 7 payments
  11. Other $6,477 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

1,475

Median for Interventional Pain Management: 1,220

Drug cost

$42,995

Median for Interventional Pain Management: $39,344

Branded share of claims

64.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 421 $11,244
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 381 $9,227
Fentanyl Generic 68 $8,439
Oxycodone Hcl Generic 193 $5,053
Morphine Sulfate Er Morphine Sulfate Brand 141 $3,689
Tramadol Hcl Generic 106 $1,693
Pregabalin Generic 54 $1,511
Morphine Sulfate Generic 45 $1,038
Gabapentin Generic 16 $470
Hydromorphone Hcl Generic 18 $305

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$77,861

Medicare's payments for the services billed

Medicare patients

260

Average age 74

Services billed

894

163 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 39%
Diabetes 37%
Chronic kidney disease 33%
Depression 32%
Osteoporosis 25%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record